For the 12 months ended December 31, 2008, net loss attributable to
common stockholders was $81.25 million, or $3.25 per share, compared to a net loss attributable to common stockholders of $61.19 million, or $2.65 per share, for the same period of 2007.
Total revenue for the fourth quarter of 2008 was $236,000, compared to $152,000 in the fourth quarter of 2007. For the 12 months ended December 31, 2008, the company reported revenues of $475,000, compared to $731,000 for the same period in 2007.
John Babich, CEO, president and chief scientific officer of Molecular Insight, said: “As we exited 2008, we re-prioritized our product pipeline and target markets and reduced operating expenses to establish a firmer financial footing for the company.
“During the year we reached several clinical milestones that increased the value of our programs and the product portfolio while reducing regulatory risks. We benefited from additional healthcare industry expertise provided by our new board members, and from the clarity and depth that was added to the management team.”